论文部分内容阅读
血液制品是由健康人血浆或经特异免疫的人血浆,经分离、提纯或由重组DNA技术制备的血浆蛋白组分,以及血液细胞有形成分,如人血白蛋白、人免疫球蛋白、人凝血因子(天然或重组的)等,用于治疗和被动免疫预防[1]。随着医学科学的进步和输血行业的不断发展,血液制品的安全性愈来愈受到人们的关注。通过调查与分析影响血液制品质量的主要因素,笔者认为应从血液采集与成分制备、血液储存与运输、临床使用等具体环节着手,采取综合整治措施,建立相关环节质量管理体系并深入贯彻执行,从而最大限度地利用血资源和保证临床输血安全。
A blood product is a plasma protein component that is isolated, purified, or prepared by recombinant DNA technology, as well as blood cell-specific components such as human serum albumin, human immunoglobulin, human immunoglobulin, human immunoglobulin, Clotting factor (natural or recombinant), etc., for the treatment and passive immune prevention [1]. With the progress of medical science and the continuous development of blood transfusion industry, the safety of blood products has drawn more and more attention. By investigating and analyzing the main factors affecting the quality of blood products, the author believes that specific measures such as blood collection and composition preparation, blood storage and transportation, clinical use should be taken and comprehensive measures should be taken to establish relevant quality management system and thoroughly implement it. Maximize the use of blood resources and ensure the safety of clinical transfusion.